Cardiorenal evidence review: CKD progression and cardiovascular outcomes
Nonsteroidal mineralocorticoid receptor antagonist · Evidence Stability Review
CKD associated with Type 2 Diabetes
No material change shown for current intended use, subject to existing caveats.
Sourced from FDA labels, pivotal trial publications, and two major guideline bodies. Two phase 3 trials (n=13,026 pooled) with consistent kidney and cardiovascular composite outcomes. Guideline recommendations strengthened from suggested to recommended (Level A) over the observation window.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2020-10 FIDELIO-DKD primary results published
- 2022-08 FDA label expansion to include CV indication
- 2024-05 KDIGO guidance elevated recommendation to Level A · Illustrative
Metabolic evidence example (T1D)
Anti-CD3 monoclonal antibody · Regulatory Review
Type 1 Diabetes
Observable movement within the stated review window; no conclusion is implied.
Historical example of evidence movement preceding formal regulatory recognition.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2022-11 First phase 3 readout in T1D population
- 2023-07 Advisory committee discussion
- 2024-02 Label expansion in comparator jurisdiction
Sample Review Package: Restriction Review for Amyloid-Directed Therapy in Early Alzheimer's Disease
Amyloid-directed therapy · Coverage Review
Early Alzheimer's Disease
Evidence-supported scope has changed relative to stated use; a qualified reviewer should take another look.
A broad coverage topic narrowed to one testable disputed claim, a one-page committee baseline, and a source-bound audit appendix. Public-domain concepts only.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2021-06 Accelerated approval based on surrogate endpoint
- 2023-01 CMS National Coverage Determination issued
- 2024-07 Confirmatory trial CDR-SB results published
Neurodegenerative review (Alzheimer's)
Anti-amyloid monoclonal antibody · Efficacy Review
Alzheimer's Disease
Observable movement within the stated review window; no conclusion is implied.
Historical example separating source-supported efficacy questions from public speculation.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2023-01 Pre-specified subgroup analysis by APOE ε4 status published
- 2023-09 Label expansion from accelerated to traditional approval on confirmatory efficacy data · Illustrative
- 2024-12 Replication of the primary efficacy endpoint in a second phase 3 population · Illustrative
Semaglutide: from high-risk comorbidity settings to general obesity weight management
GLP-1 receptor agonist · Population Drift Review
Type 2 Diabetes / Obesity
Evidence-supported scope has changed relative to stated use; a qualified reviewer should take another look.
The same molecule is now being promoted in a broader population than the pivotal trials primarily studied. The move from high-risk diabetic or cardiovascular settings to general weight-management settings changes the strength of the supporting evidence and the review action.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2017-12 Initial FDA approval for Type 2 Diabetes
- 2021-06 FDA approval for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity
- 2023-11 SELECT trial cardiovascular outcomes published
- 2025-01 CMS coverage determination for obesity indication issued · Illustrative
GLP-1 receptor agonist claim history: diabetes to obesity indication
GLP-1 receptor agonist · Provenance Review
Type 2 Diabetes / Obesity
Observable movement within the stated review window; no conclusion is implied.
Reconstructed from 22 public encyclopedia revisions. Three claim families emerged: diabetes/family-history indication, obesity/weight-management indication, and a disputed pathway.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2009-01 Article created around GLP-1 agonists for type 2 diabetes
- 2010-01 Dose and family-history details added
- 2021-08 Obesity and weight-management claim drift appears
- 2023-11 Disputed pathway surfaced by reverting edit pattern
Liraglutide claim history: single-drug provenance reconstruction
Liraglutide · Provenance Review
Type 2 Diabetes / Obesity
Observable movement within the stated review window; no conclusion is implied.
Reconstructed from 20 public encyclopedia revisions. Twenty-two stable claim families emerged; two-analyst reproducibility validation is pending.
Research use: rebuild what the public record said on the cutoff date, using only documents that existed by then, and check the rebuild against what the sources actually show. Nothing published after the cutoff is allowed into the reconstruction.
Source timeline
- 2010-01 Liraglutide mentioned as under investigation in broader GLP-1 article
- 2010-01 Approval status and dosing details added
- 2012-01 Article structure stabilizes around approved indications